companiesCompany

Zymeworks

Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).

Azymetric bispecific platform; ZW191 folate receptor ADC (52% ORR in pretreated ovarian/endometrial at AACR 2026); royalties on zanidatamab.

Headquarters

Vancouver, CA

Type

biotech · ZYME

Website

www.zymeworks.com

Products

ApprovedBiparatopic bispecific antibody (HER2)

Zanidatamab · Ziihera

Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.

Connected

Pages like this

not linked directly; found by shared links

Trial
HERIZON-BTC-302
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma).
Company
Jazz Pharmaceuticals
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma), HER2-positive breast cancer.
Target
HER3
Shares Biliary tract cancer (cholangiocarcinoma), HER2-positive breast cancer.
Technology
Bispecific antibodies
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma), HER2-positive breast cancer.
Pathway
Receptor tyrosine kinase activation
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma), HER2-positive breast cancer.

cancers

2

Biliary tract cancer (cholangiocarcinoma)HER2-positive breast cancer

fronts

2

Antibody-Drug Conjugates Targeted Therapy

drugs

1

ApprovedBiparatopic bispecific antibody (HER2)

Zanidatamab · Ziihera